Abstract
Hereditary leiomyomatosis and renal cell cancer (HLRCC, also known as multiple cutaneous and uterine leiomyomatosis, MCUL) is a highly penetrant autosomal dominant tumor predisposition syndrome characterized by benign leiomyomas of the skin and the uterus. Renal cell carcinomas, occurring in a subset of the HLRCC families, are exceptionally aggressive. Therefore careful, frequent surveillance strategies are recommended. Association of malignant smooth-muscle tumors, leiomyosarcomas, with HLRCC has been observed but the risk appears to be smaller than initially estimated. To date inactivating heterozygous mutations in the fumarate hydratase (FH, fumarase) gene, predisposing to HLRCC, have been found in approximately 180 families worldwide. The most extensively studied hypothesis on molecular mechanisms of HLRCC tumorigenesis is activation of the hypoxia pathway due to aberrant stabilization of the HIF1 transcription factor. HIF1 regulates transcription of genes relevant for vascularization, glucose transport and glycolysis, processes that facilitate tumor growth. However, additional mechanisms underlying tumor formation are likely to exist.
Similar content being viewed by others
Abbreviations
- α-KG:
-
α-ketoglutarate
- CDC:
-
Collecting duct carcinoma
- CLM:
-
Cutaneous leiomyoma
- FH:
-
Fumarate hydratase
- FHD:
-
Fumarate hydratase deficiency
- FIH:
-
Factor inhibiting HIF
- HIF1:
-
Hypoxia inducible factor 1
- HLRCC:
-
Hereditary leiomyomatosis and renal cell cancer
- HPRC:
-
Hereditary papillary renal carcinoma
- GLUT1:
-
Glucose transporter 1
- LDHA:
-
Lactate dehydrogenase A
- LOH:
-
Loss of heterozygosity
- MCUL:
-
Multiple cutaneous and uterine leiomyomatosis
- MLPA:
-
Multiplex ligation-dependent probe amplification
- MRI:
-
Magnetic resonance imaging
- PET-CT:
-
Positron emission tomography-computed tomography
- PHD:
-
Prolyl hydroxylase domain protein
- RCC:
-
Renal cell cancer
- SDHA/B/C/D:
-
Succinate dehydrogenase subunit A, B, C or D
- TCA cycle:
-
Tricaboxylic acid cycle
- ULM:
-
Uterine leiomyoma
- ULMS:
-
Uterine leiomyosarcoma
- VEGFA:
-
Vascular endothelial growth factor A
- VEFGR:
-
Vascular endothelial growth factor receptor
- VHL:
-
Von Hippel Lindau syndrome
References
Reed WB, Walker R, Horowitz R (1973) Cutaneous leiomyomata with uterine leiomyomata. Acta Derm Venereol 53:409–416
Launonen V, Vierimaa O, Kiuru M et al (2001) Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA 98:3387–3392
Alam NA, Bevan S, Churchman M et al (2001) Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. Am J Hum Genet 68:1264–1269
Tomlinson IP, Alam NA, Rowan AJ et al (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30:406–410
Alam NA, Barclay E, Rowan AJ et al (2005) Clinical features of multiple cutaneous and uterine leiomyomatosis: an underdiagnosed tumor syndrome. Arch Dermatol 141:199–206
Stewart L, Glenn GM, Stratton P et al (2008) Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer. Arch Dermatol 144:1584–1592
Zinn AB, Kerr DS, Hoppel CL (1986) Fumarase deficiency: a new cause of mitochondrial encephalomyopathy. N Engl J Med 315:469–475
Deschauer M, Gizatullina Z, Schulze A et al (2006) Molecular and biochemical investigations in fumarase deficiency. Mol Genet Metab 88:146–152
Petrova-Benedict R, Robinson BH, Stacey TE et al (1987) Deficient fumarase activity in an infant with fumaricacidemia and its distribution between the different forms of the enzyme seen on isoelectric focusing. Am J Hum Genet 40:257–266
Bayley JP, Launonen V, Tomlinson IP (2008) The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. BMC Med Genet 9:20
Smit DL, Mensenkamp AR, Badeloe S et al. (2010) Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis. Clin Genet
Ahvenainen T, Lehtonen HJ, Lehtonen R et al (2008) Mutation screening of fumarate hydratase by multiplex ligation-dependent probe amplification: detection of exonic deletion in a patient with leiomyomatosis and renal cell cancer. Cancer Genet Cytogenet 183:83–88
Ritzmann S, Hanneken S, Neumann NJ et al (2006) Type 2 segmental manifestation of cutaneous leiomyomatosis in four unrelated women with additional uterine leiomyomas (Reed’s syndrome). Dermatology 212:84–87
Toro JR, Nickerson ML, Wei MH et al (2003) Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 73:95–106
Wei MH, Toure O, Glenn GM et al (2006) Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 43:18–27
Badeloe S, van Geest AJ, van Marion AM et al (2008) Absence of fumarate hydratase mutation in a family with cutaneous leiomyosarcoma and renal cancer. Int J Dermatol 47(Suppl 1):18–20
Cramer SF, Patel A (1990) The frequency of uterine leiomyomas. Am J Clin Pathol 94:435–438
Flake GP, Andersen J, Dixon D (2003) Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 111:1037–1054
Pritts EA, Parker WH, Olive DL (2009) Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril 91:1215–1223
D’Angelo E, Prat J (2010) Uterine sarcomas: a review. Gynecol Oncol 116:131–139
Tavassoli FA, Devilee P (eds) (2003) World Health Organization classification of tumours: pathology & genetics of tumours of the breast and female genital organs. IARC Press, Lyon
Kiuru M, Launonen V, Hietala M et al (2001) Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. Am J Pathol 159:825–829
Lehtonen HJ, Kiuru M, Ylisaukko-Oja SK et al (2006) Increased risk of cancer in patients with fumarate hydratase germline mutation. J Med Genet 43:523–526
Lehtonen HJ (2008) Molecular and clinical characteristics of tricarboxylic acid cycle-associated tumors. Dissertation, University of Helsinki
Ylisaukko-oja SK, Kiuru M, Lehtonen HJ et al (2006) Analysis of fumarate hydratase mutations in a population-based series of early onset uterine leiomyosarcoma patients. Int J Cancer 119:283–287
Lehtonen HJ, Blanco I, Piulats JM et al (2007) Conventional renal cancer in a patient with fumarate hydratase mutation. Hum Pathol 38:793–796
Wortham NC, Alam NA, Barclay E et al (2006) Aberrant expression of apoptosis proteins and ultrastructural aberrations in uterine leiomyomas from patients with hereditary leiomyomatosis and renal cell carcinoma. Fertil Steril 86:961–971
Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353:2477–2490
Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds) (2004) World Health Organization classification of tumours: pathology & genetics of tumours of the urinary system and male genital organs. IARC Press, Lyon
Koski TA (2010) Molecular genetic background of tumours in hereditary leiomyomatosis and renal cell cancer syndrome. Dissertation, University of Helsinki
Alrashdi I, Levine S, Paterson J et al (2010) Hereditary leiomyomatosis and renal cell carcinoma: very early diagnosis of renal cancer in a paediatric patient. Fam Cancer 9:239–243
Kiuru M, Launonen V (2004) Hereditary leiomyomatosis and renal cell cancer (HLRCC). Curr Mol Med 4:869–875
Alam NA, Rowan AJ, Wortham NC et al (2003) Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet 12:1241–1252
Chan I, Wong T, Martinez-Mir A et al (2005) Familial multiple cutaneous and uterine leiomyomas associated with papillary renal cell cancer. Clin Exp Dermatol 30:75–78
Chuang GS, Martinez-Mir A, Engler DE et al (2006) Multiple cutaneous and uterine leiomyomata resulting from missense mutations in the fumarate hydratase gene. Clin Exp Dermatol 31:118–121
Chuang GS, Martinez-Mir A, Geyer A et al (2005) Germline fumarate hydratase mutations and evidence for a founder mutation underlying multiple cutaneous and uterine leiomyomata. J Am Acad Dermatol 52:410–416
Refae MA, Wong N, Patenaude F et al (2007) Hereditary leiomyomatosis and renal cell cancer: an unusual and aggressive form of hereditary renal carcinoma. Nat Clin Pract Oncol 4:256–261
Badeloe S, van Geel M, van Steensel MA et al (2006) Diffuse and segmental variants of cutaneous leiomyomatosis: novel mutations in the fumarate hydratase gene and review of the literature. Exp Dermatol 15:735–741
Frey MK, Worley MJ Jr, Heyman KP et al (2010) A case report of hereditary leiomyomatosis and renal cell cancer. Am J Obstet Gynecol 202:e8–e9
Grubb RL 3rd, Franks ME, Toro J et al (2007) Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 177:2074–2079 discussion 2079–80
Merino MJ, Torres-Cabala C, Pinto P et al (2007) The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 31:1578–1585
Delahunt B, Eble JN (1997) Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 10:537–544
Badeloe S, van Spaendonck-Zwarts KY, van Steensel MA et al (2009) Wilms tumour as a possible early manifestation of hereditary leiomyomatosis and renal cell cancer? Br J Dermatol 160:707–709
Koski TA, Lehtonen HJ, Jee KJ et al (2009) Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer. Genes Chromosomes Cancer 48:544–551
Terada N, Ichioka K, Matsuta Y et al (2002) The natural history of simple renal cysts. J Urol 167:21–23
Carrim ZI, Murchison JT (2003) The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. Clin Radiol 58:626–629
Pollard PJ, Spencer-Dene B, Shukla D et al (2007) Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway. Cancer Cell 11:311–319
Mandriota SJ, Turner KJ, Davies DR et al (2002) HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1:459–468
Ylisaukko-oja SK, Cybulski C, Lehtonen R et al (2006) Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma. Eur J Hum Genet 14:880–883
Lamba M, Verma S, Prokopetz R et al (2005) Multiple cutaneous and uterine leiomyomas associated with gastric GIST. J Cutan Med Surg 9:332–335
Campione E, Terrinoni A, Orlandi A et al (2007) Cerebral cavernomas in a family with multiple cutaneous and uterine leiomyomas associated with a new mutation in the fumarate hydratase gene. J Invest Dermatol 127:2271–2273
Varol A, Stapleton K, Roscioli T (2006) The syndrome of hereditary leiomyomatosis and renal cell cancer (HLRCC): the clinical features of an individual with a fumarate hydratase gene mutation. Australas J Dermatol 47:274–276
Matyakhina L, Freedman RJ, Bourdeau I et al (2005) Hereditary leiomyomatosis associated with bilateral, massive, macronodular adrenocortical disease and atypical Cushing syndrome: a clinical and molecular genetic investigation. J Clin Endocrinol Metab 90:3773–3779
Carvajal-Carmona LG, Alam NA, Pollard PJ et al (2006) Adult leydig cell tumors of the testis caused by germline fumarate hydratase mutations. J Clin Endocrinol Metab 91:3071–3075
McKelvey KD Jr, Siraj S, Kelsay J et al (2010) Male infertility associated with hereditary leiomyomatosis and renal cell carcinoma. Fertil Steril 93:2075.e1–2075.e2
Kiuru M, Lehtonen R, Arola J et al (2002) Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res 62:4554–4557
Kiuru M, Lehtonen R, Eerola H et al (2005) No germline FH mutations in familial breast cancer patients. Eur J Hum Genet 13:506–509
Bevan S, Edwards SM, Ardern Jones A et al (2003) Germline mutations in fumarate hydratase (FH) do not predispose to prostate cancer. Prostate Cancer Prostatic Dis 6:12–14
Lehtonen R, Kiuru M, Vanharanta S et al (2004) Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol 164:17–22
Lehtonen R, Kiuru M, Rokman A et al (2003) No fumarate hydratase (FH) mutations in hereditary prostate cancer. J Med Genet 40:e19
Barker KT, Bevan S, Wang R et al (2002) Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomas. Br J Cancer 87:446–448
Gross KL, Panhuysen CI, Kleinman MS et al (2004) Involvement of fumarate hydratase in nonsyndromic uterine leiomyomas: genetic linkage analysis and FISH studies. Genes Chromosomes Cancer 41:183–190
Maradin M, Fumic K, Hansikova H et al (2006) Fumaric aciduria: mild phenotype in a 8-year-old girl with novel mutations. J Inherit Metab Dis 29:683
Shih VE, Mandell R (2009) Fumarate hydratase deficiency. Available via http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=fum
Kinsella BT, Doonan S (1986) Nucleotide sequence of a cDNA coding for mitochondrial fumarase from human liver. Biosci Rep 6:921–929
Tolley E, Craig I (1975) Presence of two forms of fumarase (Fumarate Hydratase E.C. 4.2.1.2) in mammalian cells: immunological characterization and genetic analysis in somatic cell hybrids. Confirmation of the assignment of a gene necessary for the enzyme expression to human chromosome 1. Biochem Genet 13:867–883
Sass E, Karniely S, Pines O (2003) Folding of fumarase during mitochondrial import determines its dual targeting in yeast. J Biol Chem 278:45109–45116
Lorenzato A, Olivero M, Perro M et al (2008) A cancer-predisposing “hot spot” mutation of the fumarase gene creates a dominant negative protein. Int J Cancer 122:947–951
Rongioletti F, Fausti V, Ferrando B et al (2010) A novel missense mutation in fumarate hydratase in an italian patient with a diffuse variant of cutaneous leiomyomatosis (Reed’s syndrome). Dermatology 221:378–380
Vahteristo P, Koski TA, Naatsaari L et al (2010) No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome. Fam Cancer 9:245–251
Gottlieb E, Tomlinson IP (2005) Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 5:857–866
Hao HX, Khalimonchuk O, Schraders M et al (2009) SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 325:1139–1142
Semenza GL (2010) Oxygen homeostasis. Wiley Interdiscip Rev Syst Biol Med 2:336–361
O’Flaherty L, Adam J, Heather LC et al (2010) Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism. Hum Mol Genet 19:3844–3851
Selak MA, Armour SM, MacKenzie ED et al (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7:77–85
Pollard PJ, Briere JJ, Alam NA et al (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14:2231–2239
Isaacs JS, Jung YJ, Mole DR et al (2005) HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8:143–153
MacKenzie ED, Selak MA, Tennant DA et al (2007) Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol Cell Biol 27:3282–3289
Pan Y, Mansfield KD, Bertozzi CC et al (2007) Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol 27:912–925
Koivunen P, Hirsila M, Remes AM et al (2007) Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem 282:4524–4532
Catherino WH, Mayers CM, Mantzouris T et al (2007) Compensatory alterations in energy homeostasis characterized in uterine tumors from hereditary leiomyomatosis and renal cell cancer. Fertil Steril 88:1039–1048
Vanharanta S, Pollard PJ, Lehtonen HJ et al (2006) Distinct expression profile in fumarate-hydratase-deficient uterine fibroids. Hum Mol Genet 15:97–103
Pollard P, Wortham N, Barclay E et al (2005) Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. J Pathol 205:41–49
Ashrafian H, O’Flaherty L, Adam J et al (2010) Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis. Cancer Res 70:9153–9165
Raimundo N, Ahtinen J, Fumic K et al (2008) Differential metabolic consequences of fumarate hydratase and respiratory chain defects. Biochim Biophys Acta 1782:287–294
Greijer AE, van der Wall E (2004) The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 57:1009–1014
Costa B, Dettori D, Lorenzato A et al (2010) Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis. FASEB J 24:2680–2688
Bayley JP, Devilee P (2010) Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree? Curr Opin Genet Dev 20:324–329
Sudarshan S, Sourbier C, Kong HS et al (2009) Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 29:4080–4090
Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8:519–530
Gillies RJ, Gatenby RA (2007) Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? J Bioenerg Biomembr 39:251–257
Bui T, Thompson CB (2006) Cancer’s sweet tooth. Cancer Cell 9:419–420
Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773
Yogev O, Yogev O, Singer E et al (2010) Fumarase: a mitochondrial metabolic enzyme and a cytosolic/nuclear component of the DNA damage response. PLoS Biol 8:e1000328
Pithukpakorn M, Toro JR (2007) Hereditary leiomyomatosis and renal cell cancer. Available via http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=hlrcc
Parker WH (2007) Uterine myomas: management. Fertil Steril 88:255–271
Catherino WH, Malik M, Driggers P et al (2010) Novel, orally active selective progesterone receptor modulator CP8947 Inhibits leiomyoma cell proliferation without adversely affecting endometrium or myometrium. J Steroid Biochem Mol Biol 122:279–286
Linehan WM, Pinto PA, Bratslavsky G et al (2009) Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer 115:2252–2261
Pavlovich CP, Schmidt LS (2004) Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer 4:381–393
Gupta GN, Peterson J, Thakore KN et al (2010) Oncological outcomes of partial nephrectomy for multifocal renal cell carcinoma greater than 4 Cm. J Urol 184:59–63
Singer EA, Bratslavsky G, Linehan WM et al (2010) Targeted therapies for non-clear renal cell carcinoma. Target Oncol 5:119–129
Vladimir AV, Youfeng Y, Beatriz AW et al (2010) 367 evaluation of the VEGF-VEGF receptor axis in hereditary leiomyomatosis renal cell carcinoma (HLRCC) kidney tumors. J Urol 183
Airley RE, Mobasheri A (2007) Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 53:233–256
Yang Y, Valera VA, Padilla-Nash HM et al (2010) UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet 196:45–55
Xie H, Valera VA, Merino MJ et al (2009) LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 8:626–635
Tennant DA, Frezza C, MacKenzie ED et al (2009) Reactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell death. Oncogene 28:4009–4021
Temes E, Martin-Puig S, Acosta-Iborra B et al (2005) Activation of HIF-prolyl hydroxylases by R59949, an inhibitor of the diacylglycerol kinase. J Biol Chem 280:24238–24244
Gao P, Zhang H, Dinavahi R et al (2007) HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12:230–238
Sourbier C, Valera-Romero V, Giubellino A et al (2010) Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma. Cell Cycle 9:4183–4189
Pollard PJ, Ratcliffe PJ (2009) Cancer. Puzzling patterns of predisposition. Science 324:192–194
Acknowledgments
Prof Lauri Aaltonen is acknowledged for the comments on the manuscript. Prof Kristiina Aittomäki and Dr Pia Alhopuro are thanked for consultation on surveillance guidelines and Prof Johanna Arola for help on histopathological items. Ms Johanna Kondelin is thanked for editing the text. Figure 1 is presented by the courtesy of Dr Erik Björck and Fig. 3 is formulated with kind help of Dr Iulia Diaconu.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lehtonen, H.J. Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. Familial Cancer 10, 397–411 (2011). https://doi.org/10.1007/s10689-011-9428-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10689-011-9428-z